91.60%
This comes two days after Indian Prime Minister Narendra Modi was administered a dose of Covaxin as he kicked off the largest phase of COVID-19 vaccination in India. Covaxin is one of two coronavirus vaccines approved by the India drug regulator. The drug had earlier received clearance for emergency use.
Advertisement
Bharat Biotech conducted a study on 25,800 participants who received a vaccine or placebo in a 1:1 ratio. The results showed that the vaccine candidate was well tolerated. It conducted the trials in partnership with India’s medical research organisation, ICMR.
Earlier, the Indian drug regulator s approval triggered a row of criticism from experts pointing to a lack of efficacy data at that time.
Bharat Biotech not allowed to conduct simultaneous Phase I, II trials for its intranasal COVID-19 vaccine
The SEC has reportedly refused to consider Bharat Biotech’s request and said it wants the Indian vaccine maker to first conduct the phase I trials and submit the immunogenicity data before moving on to the next stage.
Bharat Biotech has claimed that the non-invasive, single-dose vaccine will be far easier to administer.
Bharat Biotech has not been allowed to conduct simultaneous phase I and phase II trials for its nasal COVID-19 vaccine candidate, reported CNBC-TV18 on January 19.
Sources say SEC did not consider the request of Bharat Biotech to conduct both Phase 1 & 2 trials simultaneously for its nasal #vaccine candidate. SEC wants co to first conduct phase 1 & submit immunogenicity data before seeking approval for phase 2 pic.twitter.com/qNg4kOpGhH
Som said if the Muslims in India do not have faith in Indian scientists, the Prime Minister and the police administration of the country, then they should leave India and go to Pakistan.
Bharat Biotech inks deal with Precisa Medicamentos for supply of COVAXIN to Brazil
Bharat Biotech has informed that the supplies of Covaxin will be prioritised for the public market, through a direct procurement by the Government of Brazil.
Bharat Biotech s Covaxin was granted restricted emegency use approval in clinical trial mode on January 2.
Hyderabad-based Bharat Biotech announced on January 12 that it has signed an agreement with Precisa Medicamentos to supply its coronavirus vaccine Covaxin to Brazil.
The vaccine maker said a team from Precisa Medicamentos had visited its facility last week to discuss potential export possibilities of Covaxin. They had met Dr Krishna Ella on January 7 and 8 and were joined by Ambassador of Brazil to India André Aranha Corrêa do Lago, who “expressed his keen interest on behalf of the Government of Brazil to procure Covaxin”.